{"id":"cd47","name":"CD47","symbol":"CD47","route":"/targets/cd47/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1682","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000196776","uniprot":"https://www.uniprot.org/uniprotkb/Q08722/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q08722","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3714583","open-targets":"https://platform.opentargets.org/target/ENSG00000196776","civic":"https://civicdb.org/genes/961/summary","oncokb":"https://www.oncokb.org/gene/CD47","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CD47","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CD47","depmap":"https://depmap.org/portal/gene/CD47?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000196776-CD47","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/961","omim":"https://www.omim.org/entry/601028"}],"products":[{"id":"ak117","name":"AK117","status":"phase-3","modality":"monoclonal antibody (AK117 is ligufalimab; INN stem -mab; form not stated in the registry record)","route":"/drugs/ak117/"},{"id":"magrolimab","name":"Magrolimab","status":"withdrawn","modality":"Monoclonal antibody (anti-CD47)","route":"/drugs/magrolimab/"},{"id":"peluntamig","name":"Peluntamig","status":"phase-2","modality":"bispecific antibody","route":"/drugs/peluntamig/"},{"id":"spevatamig","name":"Spevatamig","status":"phase-2","modality":"bispecific antibody","route":"/drugs/spevatamig/"}],"trials":[{"id":"nct04778397","name":"Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated","nct":"NCT04778397","phase":"3"},{"id":"nct05079230","name":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia","nct":"NCT05079230","phase":"3"},{"id":"nct04313881","name":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","nct":"NCT04313881","phase":"3"},{"id":"nct06601335","name":"A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","nct":"NCT06601335","phase":"3","status":"recruiting"},{"id":"nct05382442","name":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","nct":"NCT05382442","phase":"2","status":"active"},{"id":"nct05227664","name":"A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer","nct":"NCT05227664","phase":"2","status":"active"},{"id":"nct07245446","name":"A Study of Ivonescimab in First-Line ES-SCLC","nct":"NCT07245446","phase":"2","status":"recruiting"},{"id":"nct05229497","name":"A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors","nct":"NCT05229497","phase":"1/2","status":"active"},{"id":"nct05652686","name":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","nct":"NCT05652686","phase":"1/2","status":"recruiting"},{"id":"nct04980885","name":"A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia","nct":"NCT04980885","phase":"1/2","status":"active"},{"id":"nct05482893","name":"Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junct","nct":"NCT05482893","phase":"1/2","status":"recruiting"}],"pathways":["cd47-sirpa","myc","myeloid-suppression-axis","tumor-microenvironment"],"companies":["akeso","alx-oncology","gilead","phanes-therapeutics"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}